SPY334.04-0.15 -0.04%
DIA275.32-0.58 -0.21%
IXIC11,130.29+12.76 0.11%

MediciNova Announces 'Development Progress' On Intranasal Formulation Of SARS-CoV-2 Vaccine For COVID-19

New information for Spike protein specific antibody response after a single intranasal dose LA JOLLA, Calif., Sept. 01, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global

 · 

New information for Spike protein specific antibody response after a single intranasal dose

LA JOLLA, Calif., Sept. 01, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced development progress on its intranasal SARS-CoV-2 vaccine for COVID-19 utilizing BC-PIV, a viral vector platform technology developed by Mie University and BioComo.

We have designed multiple vaccine prototypes using a number of combinations of modality and antigen which are highly expected to induce immunity. Among these multiple prototypes, we have confirmed that the SARS-CoV-2 specific protein antigen mounted on their membrane surfaces binds with ACE2, which is a known receptor of SARS-CoV-2.

We also examined the induction of specific antibodies against the SARS-CoV-2 Spike protein by inoculating mice with these vaccine prototypes using a single intranasal dose. Induction of specific antibodies against this SARS-CoV-2 antigen was measured using ELISA tests and compared. We narrowed the vaccine prototypes down to several candidates that induced a stronger specific antibody response for future development.

We are currently in the process of analyzing neutralizing antibody titers through in-vivo testing. In addition to this, we plan to conduct the following tests.

  1. Induction of mucosal immunity and measurement of the antibody titer;
  2. Analysis of cell-mediated immunity (CD4/CD8-positive T cells);
  3. In-vivo study to test the vaccine prototype’s efficacy by nasal spray to prevent viral infection.

BioComo, our development partner, has already converted packaging cells into a master cell bank. We are preparing to start production of vaccine candidates for safety toxicology tests and clinical trials.

Yuichi Iwaki, M.D., Ph.D., President and Chief Executive Officer of MediciNova, Inc., commented, "We are very pleased to confirm that we now have multiple COVID-19 vaccine prototypes that induced a strong antibody response against the SARS-CoV-2 Spike protein after administration of only one intranasal dose. This is a critical step in our development of an effective vaccine. We look forward to reporting additional results as soon as possible.”